Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: Clinicopathological features of 24 patients

Journal of Rheumatology

Volumn 36, Issue 12, 2009, Pages 2780-2787

  Favia, Gianfranco ^a   Pilolli, Giovanni Pietro ^a   Maiorano, Eugenio ^a  

^a Faculty of Medicine   (France)

Author keywords

Bisphosphonates; Bone; Jawbone; Osteonecrosis; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CORTICOSTEROID; IBANDRONIC ACID; RISEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE; CLINICAL ARTICLE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; DENTAL CARE; DENTURE; FEMALE; HUMAN; JAW; JAW OSTEONECROSIS; JAW RADIOGRAPHY; MANDIBLE; MAXILLA; MOUTH HYGIENE; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TOOTH EXTRACTION; TOOTH IMPLANTATION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; DENTAL CARE; DIPHOSPHONATES; FEMALE; HUMANS; JAW DISEASES; MIDDLE AGED; MULTIPLE MYELOMA; OSTEONECROSIS; OSTEOPOROSIS;

EID: 72449200764     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090455     Document Type: Article

References (36)

1. McClung MR. Bisphosphonates. Endocrinol Metab Clin North Am 2003;32:253-271
2. Rodan GA, Fleisch HA. Bisphosphonates: Mechanisms of action. J Clin Invest 1996;97:2692-2696
3. Santini D, Vespasiani Gentilucci U, Vincenzi B, Picardi A, Vasaturo F, et al. The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol 2003;14:1468-1476 (Pubitemid 37304600)
4. Boissier S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD, et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 1997;57:3890-3894 (Pubitemid 27427670)
5. Wysowski DK. Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009;360:89-90.
6. Loke YK, Jeevanantham V, Singh S. Bisphosphonates and atrial fibrillation: systematic review and meta-analysis. Drug Saf 2009;32:219-228
7. Conte P, Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist 2004;9:28-37. (Pubitemid 39363166)
8. Ibrahim T, Barbanti F, Giorgio-Marrano G, Mercatali L, Ronconi S, Vicini C, et al. Osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: a retrospective study. Oncologist 2008;13:330-336 (Pubitemid 351679909)
9. Hewitt C, Farah C. Bisphosphonate-related osteonecrosis of the jaws: a comprehensive review. J Oral Pathol Med 2007;36:319-328 (Pubitemid 46889876)
10. Cavanna L, Bertè R, Arcari A, Mordenti P, Pagani R, Vallisa D. Osteonecrosis of the jaw. A newly emerging site-specific osseous pathology in patients with cancer treated with bisphosphonates. Report of five cases and review of the literature. Eur J Intern Med 2007;18:417-422 (Pubitemid 47211940)
11. Bagan JV, Jimenez Y, Murillo J, Hernandez S, Poveda R, Sanchis JM, et al. Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases. Oral Oncol 2006;42:327-329 (Pubitemid 43246766)
12. American Dental Association Council on Scientific Affairs. Dental management of patients receiving oral bisphosphonate therapy: Expert panel recommendations. J Am Dent Assoc 2006;137:1144-1150
13. Rizzoli R, Burlet N, Cahall D, Delmas PD, Eriksen EF, Felsenberg D, et al. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 2008;42:841-847
14. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;102:433-441 (Pubitemid 44403162)
15. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-1117
16. Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 2003;61:1104-1107 (Pubitemid 37064708)
17. Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007;65:2397-2410
18. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 2004;62:527-534 (Pubitemid 38542516)
19. Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate associated osteonecrosis of mandibular and maxillary bone: An emerging oral complication of supportive cancer therapy. Cancer 2005;104:83-93.
20. Migliorati CA. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 2003;21:4253-4254
21. Melo MD, Obeid G. Osteonecrosis of the maxilla in a patient with a history of bisphosphonate therapy. J Can Dent Assoc 2005;71:111-113 (Pubitemid 41679824)
22. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005;353:99-102.
23. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23:8580-8587 (Pubitemid 46211499)
24. Watts NB, Chines A, Olszynski WP, McKeever CD, McClung MR, Zhou X, et al. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 2008;19:365-372 (Pubitemid 351199181)
25. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C. Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002;23:570-578 (Pubitemid 34925651)
26. Hilding M, Aspenberg P. Postoperative clodronate decreases prosthetic migration: 4-year follow-up of a randomized radiostereometric study of 50 total knee patients. Acta Orthop 2006;77:912-916 (Pubitemid 46269197)
27. Chapurlat RD, Delmas PD. Drug insight: Bisphosphonates for postmenopausal osteoporosis. Nat Clin Pract Endocrinol Metab 2006;2:211-219
28. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-1491
29. Brooks JK, Gilson AJ, Sindler AJ, Ashman SG, Schwartz KG, Nikitakis NG. Osteonecrosis of the jaws associated with use of risedronate: report of 2 new cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;103:780-786
30. Wang HL, Weber D, McCauley LK. Effect of long-term oral bisphosphonates on implant wound healing: literature review and a case report. J Periodontol 2007;78:584-594
31. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567-1575 (Pubitemid 41525412)
32. Yarom N, Yahalom R, Shoshani Y, Hamed W, Regev E, Elad S. Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int 2007;18:1363-1370 (Pubitemid 47389465)
33. Elad S, Yarom N, Hamed W, Ayalon S, Yahalom R, Regev E. Osteomyelitis and necrosis of the jaw in patients treated with bisphosphonates. A comparative study. Clin Lab Haematol 2006;28:393-398
34. Serra MP, Llorca CS, Donat FJ. Oral implants in patients receiving bisphosphonates: a review and update. Med Oral Patol Oral Cir Bucal 2008;13:E755-60.
35. American Society for Bone and Mineral Research Task Force on Osteonecrosis of the Jaw. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2008;66:1320-1321
36. Bagan JV, Jiménez Y, Gómez D, Sirera R, Poveda R, Scully C. Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates. Oral Oncol 2008;44:1088-1089 Epub 2008 Apr 8.